Clinical trials of vitamin E in coronary artery disease: Is it time to reconsider the low-density lipoprotein oxidation hypothesis?

Current Atherosclerosis Reports

Volumn 5, Issue 2, 2003, Pages 83-87

  Heinecke, Jay W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; BETA CAROTENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NICOTINIC ACID; PLACEBO; PROBUCOL; SELENIUM;

ANTIOXIDANT ACTIVITY; CLINICAL OBSERVATION; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIETARY INTAKE; DISEASE MODEL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; LIPID PEROXIDATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIMARY PREVENTION; REVIEW; TREATMENT FAILURE; VITAMIN SUPPLEMENTATION; ANIMAL; ANIMAL MODEL; BLOOD; DRUG EFFECT; OXIDATION REDUCTION REACTION;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS, LDL; MODELS, ANIMAL; OXIDATION-REDUCTION; VITAMIN E;

EID: 0038320979     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0075-1     Document Type: Review

References (43)

1. Brown MS, Goldstein JL: Koch's postulates for cholesterol. cell 1992, 71:187-189.
2. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979, 76:333-336.
3. Fogelman AM, Shechter I, Seager J, et al.: Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A 1980, 77:2214-2217.
4. HenriksenT, Mahoney EM, Steinberg D: Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A 1981, 78:6499-6507.
5. Heinecke JW, Rosen H, Chait A: Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984, 74:1890-1893.
6. Morel DW, DiCorleto PE, Chisolm GM: Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984, 4:357-363
7. Steinbrecher UP, Parthasarathy S, Leake DS, et al.: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 1984, 81:3883-3886.
8. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-1791.
9. Diaz MN, Frei B, Vita JA, Keaney JF: Antioxidants and atherosclerotic heart disease. N Engl J Med 1997, 337:408-413.
10. Heinecke JW: Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998, 141:1-15.
11. Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe Heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987, 84:7725-7729.
12. Sparrow CP, Deobber JW, Olszewski J, et al.: Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N-diphenyl-phenylenediamine. J Clin Invest 1992, 89:1885-1893.
13. Kleinveld HA, Demacker PN, Stalenhoef AF: Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits. Arterioscler Thromb 1994, 14:1386-1364.
14. Lynch SM, Frei B: Antioxidants as anti-atherogens: animal studies. In Natural Antioxidants in Hunian Health and Disease. Edited by Frei, B. Orlando FL: Academic Press; 1994.
15. Shaish A, Daugherty A, O'Sullivan F, et al.: Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995, 96:2075.
16. Kleinveld HA, Hak-Lemmers HL, Hectors MP, et al.: Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 1995, 15:290.
17. Thomas SR, Leichtweis SB, Pettersson K, et al.: Dietary cosupplementation with vitamin e and coenzyme q(10) inhibits atherosclerosis in apolipoprotein e gene knockout mice. Arterioscler Thromb Vasc Biol 2001, 21:585-593.
18. Pratico D, Tangirala RK, Rader DJ, el al.: Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nature Med 1998, 4:1189-1192.
19. Morrow JD, Roberts LJ: The isoprostanes: current knowledge and directions for future research. Biochem Pharm 1996, 51:1-12.
20. Patrono C, FitzGerald GA: Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997, 17:2309-2317.
21. Terasawa Y, Ladha Z, Leonard SW, et al.: Increased atherosclerosis in hyperlipidemic mice deficient in alpha-tocopherol transfer protein and vitamin E. Proc Natl Acad Sci U S A 2000, 97:13830-13834.
22. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40:405-412.
23. Stachman ER: Protein oxidation and aging. Science 1992, 257:1220-1224.
24. Burton GW, Ingold KU: Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci 1989, 570:7-22.
25. Bowry VW, Ingold KU, Stocker R: Vitamin E in human low density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 1992, 288(Pt 2):341-344.
26. Davi G, Alessandrini P, Mezzetti A, et al.: In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997, 17:3230-3235.
27. Meagher EA, Barry OP, Lawson JA, et al.: Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001, 285:1178-1182.
28. Stampfer M, Hennekens CH, Manson JE, et al.: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993, 328:1444-1449.
29. Rimm EB, Stampler MJ, Ascherio A, et al.: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993, 328:1450-1455.
30. Stephens NG, Parsons A, Schofield PM, et al.: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
31. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455.
32. Yusuf S, Dagenais G, Pogue J, et al.: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154-160.
33. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33.
34. Brown BC, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
35. Cheung MC, Zhao XQ, Chait A, et al.: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001, 21:1320-1326.
36. de Gaetano G: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001, 357:89-95.
37. Boaz M, Smetana S, Weinstein T et al.: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
38. Fang JC, Kinlay S, Beltrame J, et al.: Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002, 359:1108-1113.
39. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
40. Heinecke JW: Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 1999, 13:1113-1120.
41. Daugherty A, Rateri DL, Dunn JL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437.
42. Savenkova ML, Mueller DM, Heinecke JW: Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994, 269:20394-20400.
43. Hazell LJ, Stocker R: Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett 1997, 414:541-544.